Table 5. Purine metabolites in PD.
| Controls (n = 25) | Unmed PD (n = 15) | % change (p value) | |
| HX | 177±38 | 103±21 | −41.91 (0.046) |
| X | 96±6 | 82±6 | −14.15 (0.054) |
| XAN | 79±6 | 105±20 | 32.16 (0.123) |
| UA | 97±4 | 83±5 | −14.31 (0.050) |
| G | 91±5 | 84±5 | −8.08 (0.164) |
| HX/XAN | 200±35 | 116±27 | −41.83 (0.033) |
| X/XAN | 136±12 | 101±12 | −26.04 (0.021) |
| HX/UA | 183±38 | 124±21 | −32.32 (0.041) |
Data are represented as mean±SEM of percentage of plasma pool value. Control group includes both normal control subjects and healthy family members from LRRK2 PD patients who did not have G2019S mutation. HX–hypoxanthine, X–xanthosine, XAN–xanthine, UA–uric acid, G- guanosine.